-
<![CDATA[Dr Tolaney on the FDA Approval of Frontline T-DXd Plus Pertuzumab For Metastatic HER2+ Breast Cancer]]>
16 Jan 2026 01:05 GMT
… patients with unresectable or metastatic HER2-positive breast cancer.
The regulatory decision was … novo metastatic disease or recurrent HER2-positive breast cancer. Patients were randomly assigned …
-
Fast Five Quiz: Key Aspects of Metastatic Breast Cancer
15 Jan 2026 17:52 GMT
… with other breast cancer subtypes.
Learn more about breast cancer.
Clinical N3 breast cancer indicates ipsilateral … , premenopausal patients with HR-positive, HER2-negative disease should be offered …
-
Mapping cancer’s weak spots reveals new precision targets for breast cancer
15 Jan 2026 15:53 GMT
… that distinguish different breast cancer subtypes, revealing … remain poorly understood. Breast cancer is particularly heterogeneous … researchers further stratified breast cancer cell lines into … #47;HER2-positive and basal-like breast cancer subtypes.
…
-
<![CDATA[Personalized Selection of HER2+ Breast Cancer Therapies]]>
15 Jan 2026 07:54 GMT
Treatment selection in HER2-positive breast cancer is increasingly guided by disease … patient-specific factors. In early breast cancer, clinicians carefully weigh neoadjuvant versus … criteria for ADC eligibility include HER2 expression levels, prior response …
-
<![CDATA[Sequencing Beyond First Line in HER2 Positive Metastatic Breast Cancer ]]>
15 Jan 2026 14:40 GMT
This segment addresses the complex and evolving decisions surrounding treatment sequencing after progression on initial HER2 targeted therapy. The discussion explores how clinicians integrate prior response duration, pattern of progression, and patient …
-
<![CDATA[Contextualizing PFS, Safety, and Response Depth From DESTINY Breast09 in HER2 Positive Metastatic Breast Cancer ]]>
15 Jan 2026 14:40 GMT
This segment examines how clinicians should interpret progression free survival, safety, and response signals from DESTINY Breast09 within the context of established HER2 targeted evidence. Panelists discuss placing interim PFS findings alongside …
-
<![CDATA[Defining Success in Metastatic Breast Cancer Trial Design]]>
15 Jan 2026 07:54 GMT
… successful clinical trial in metastatic breast cancer is built on thoughtful design … -drug conjugate (ADC) trials in HER2-positive disease should explore earlier …
-
<![CDATA[Elacestrant Shows Potential as a Backbone For Combination Regimens in ER+/HER2- Breast Cancer]]>
13 Jan 2026 20:06 GMT
… ER)-positive/HER2-negative breast cancer, paving the way … the 2025 San Antonio Breast Cancer Symposium, Kaklami presented … within ER-positive metastatic breast cancer, tumor characteristics and … at: 2025 San Antonio Breast Cancer Symposium; December 9-12 …
-
<![CDATA[Trastuzumab, Trastuzumab Deruxtecan Show Efficacy in HER2+ Solid Tumors]]>
15 Jan 2026 07:53 GMT
… HER2-positive (HER2+) cancers. These cancers are HER2+ metastatic breast cancer, HER2-low and -ultralow metastatic breast cancer … , any HER2+ metastatic solid …
-
Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from Turkey
14 Jan 2026 10:17 GMT
… Approximately 70% of metastatic breast cancers express hormone receptors … advanced HR-positive, HER2-negative breast cancer, endocrine-based therapies … in HR+/HER2- breast cancer. NPJ Breast Cancer. 2023;9(1 … in HR+/HER2- breast cancer. J Clin Oncol. …
About
© 1995-2026